{"title":"输血实践、人口结构和生育率的变化对红细胞异体抗体流行率的影响。","authors":"Krishna G Badami, Sarah Hull, Charlotte Vanhecke","doi":"10.1111/vox.70022","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Factors affecting red blood cell (RBC) alloimmunization have changed in New Zealand (NZ). We aimed to investigate whether alloimmunization prevalence had changed as a result.</p><p><strong>Materials and methods: </strong>We calculated the prevalence (%) of patients with RBC alloantibodies among those who had antibody screening/identification done in Canterbury, NZ, during three periods: 2006-2010 (P1), 2012-2016 (P2) and 2018-2022 (P3).</p><p><strong>Results: </strong>During P1, P2 and P3, respectively, females and males numbered 58,817, 30,082; 48,775, 28,383 and 56,200, 31,443. Combining the periods, the overall alloantibody prevalence in females and males was 2.4 versus 0.9, p < 0.0001, and in those ≥60 and ≤40 years, it was 1.9 versus 1.5, p < 0.0001. Prevalence declined, especially after P2. Prevalence of the five most common alloantibodies during P1, P2 and P3, respectively, was as follows: anti-E, 0.39, 0.48, 0.37; anti-D, 0.38, 0.34, 0.27; anti-K, 0.34, 0.32, 0.22; anti-Fya, 0.18, 0.19, 0.14; anti-C, 0.17, 0.16, 0.12; all alloantibodies, 2.0, 2.1, 1.5. p-values by the chi-squared test comparing prevalence (P1 vs. P2, P1 vs. P3, P2 vs. P3, respectively) were anti-E, 0.005, 0.5, 0.0006; anti-D, 0.2, <0.0001, 0.001; anti-K, 0.5, <0.0001, 0.0001; anti-Fya, 0.6, 0.04, 0.01; anti-C, 0.6, 0.006, 0.03; all alloantibodies, 0.1, <0.0001, <0.0001.</p><p><strong>Conclusion: </strong>RBC alloantibody prevalence has declined. The chief reasons for this appear to be changes in transfusion management, NZ population mix and fertility. The decline is beneficial.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of change in transfusion practice, population mix and fertility on red blood cell alloantibody prevalence.\",\"authors\":\"Krishna G Badami, Sarah Hull, Charlotte Vanhecke\",\"doi\":\"10.1111/vox.70022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Factors affecting red blood cell (RBC) alloimmunization have changed in New Zealand (NZ). We aimed to investigate whether alloimmunization prevalence had changed as a result.</p><p><strong>Materials and methods: </strong>We calculated the prevalence (%) of patients with RBC alloantibodies among those who had antibody screening/identification done in Canterbury, NZ, during three periods: 2006-2010 (P1), 2012-2016 (P2) and 2018-2022 (P3).</p><p><strong>Results: </strong>During P1, P2 and P3, respectively, females and males numbered 58,817, 30,082; 48,775, 28,383 and 56,200, 31,443. Combining the periods, the overall alloantibody prevalence in females and males was 2.4 versus 0.9, p < 0.0001, and in those ≥60 and ≤40 years, it was 1.9 versus 1.5, p < 0.0001. Prevalence declined, especially after P2. Prevalence of the five most common alloantibodies during P1, P2 and P3, respectively, was as follows: anti-E, 0.39, 0.48, 0.37; anti-D, 0.38, 0.34, 0.27; anti-K, 0.34, 0.32, 0.22; anti-Fya, 0.18, 0.19, 0.14; anti-C, 0.17, 0.16, 0.12; all alloantibodies, 2.0, 2.1, 1.5. p-values by the chi-squared test comparing prevalence (P1 vs. P2, P1 vs. P3, P2 vs. P3, respectively) were anti-E, 0.005, 0.5, 0.0006; anti-D, 0.2, <0.0001, 0.001; anti-K, 0.5, <0.0001, 0.0001; anti-Fya, 0.6, 0.04, 0.01; anti-C, 0.6, 0.006, 0.03; all alloantibodies, 0.1, <0.0001, <0.0001.</p><p><strong>Conclusion: </strong>RBC alloantibody prevalence has declined. The chief reasons for this appear to be changes in transfusion management, NZ population mix and fertility. The decline is beneficial.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70022\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Effects of change in transfusion practice, population mix and fertility on red blood cell alloantibody prevalence.
Background and objectives: Factors affecting red blood cell (RBC) alloimmunization have changed in New Zealand (NZ). We aimed to investigate whether alloimmunization prevalence had changed as a result.
Materials and methods: We calculated the prevalence (%) of patients with RBC alloantibodies among those who had antibody screening/identification done in Canterbury, NZ, during three periods: 2006-2010 (P1), 2012-2016 (P2) and 2018-2022 (P3).
Results: During P1, P2 and P3, respectively, females and males numbered 58,817, 30,082; 48,775, 28,383 and 56,200, 31,443. Combining the periods, the overall alloantibody prevalence in females and males was 2.4 versus 0.9, p < 0.0001, and in those ≥60 and ≤40 years, it was 1.9 versus 1.5, p < 0.0001. Prevalence declined, especially after P2. Prevalence of the five most common alloantibodies during P1, P2 and P3, respectively, was as follows: anti-E, 0.39, 0.48, 0.37; anti-D, 0.38, 0.34, 0.27; anti-K, 0.34, 0.32, 0.22; anti-Fya, 0.18, 0.19, 0.14; anti-C, 0.17, 0.16, 0.12; all alloantibodies, 2.0, 2.1, 1.5. p-values by the chi-squared test comparing prevalence (P1 vs. P2, P1 vs. P3, P2 vs. P3, respectively) were anti-E, 0.005, 0.5, 0.0006; anti-D, 0.2, <0.0001, 0.001; anti-K, 0.5, <0.0001, 0.0001; anti-Fya, 0.6, 0.04, 0.01; anti-C, 0.6, 0.006, 0.03; all alloantibodies, 0.1, <0.0001, <0.0001.
Conclusion: RBC alloantibody prevalence has declined. The chief reasons for this appear to be changes in transfusion management, NZ population mix and fertility. The decline is beneficial.
期刊介绍：
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
